392 related articles for article (PubMed ID: 29294043)
1. Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma.
Takeuchi Y; Tanemura A; Tada Y; Katayama I; Kumanogoh A; Nishikawa H
Int Immunol; 2018 Feb; 30(1):13-22. PubMed ID: 29294043
[TBL] [Abstract][Full Text] [Related]
2. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
[TBL] [Abstract][Full Text] [Related]
3. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients.
Subrahmanyam PB; Dong Z; Gusenleitner D; Giobbie-Hurder A; Severgnini M; Zhou J; Manos M; Eastman LM; Maecker HT; Hodi FS
J Immunother Cancer; 2018 Mar; 6(1):18. PubMed ID: 29510697
[TBL] [Abstract][Full Text] [Related]
4. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
5. [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].
Adam J; Tomasic G; Robert C
Ann Pathol; 2017 Feb; 37(1):55-60. PubMed ID: 28111041
[TBL] [Abstract][Full Text] [Related]
6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
7. Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade.
Bochem J; Zelba H; Amaral T; Spreuer J; Soffel D; Eigentler T; Wagner NB; Uslu U; Terheyden P; Meier F; Garbe C; Pawelec G; Weide B; Wistuba-Hamprecht K
PLoS One; 2019; 14(8):e0221301. PubMed ID: 31419253
[TBL] [Abstract][Full Text] [Related]
8. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
Narducci MG; Tosi A; Frezzolini A; Scala E; Passarelli F; Bonmassar L; Monopoli A; Accetturi MP; Cantonetti M; Antonini Cappellini GC; De Galitiis F; Rosato A; Picozza M; Russo G; D'Atri S
Front Immunol; 2020; 11():579894. PubMed ID: 33072126
[TBL] [Abstract][Full Text] [Related]
9. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Buchbinder EI; Dutcher JP; Daniels GA; Curti BD; Patel SP; Holtan SG; Miletello GP; Fishman MN; Gonzalez R; Clark JI; Richart JM; Lao CD; Tykodi SS; Silk AW; McDermott DF
J Immunother Cancer; 2019 Feb; 7(1):49. PubMed ID: 30777131
[TBL] [Abstract][Full Text] [Related]
10. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
11. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
Stein JE; Soni A; Danilova L; Cottrell TR; Gajewski TF; Hodi FS; Bhatia S; Urba WJ; Sharfman WH; Wind-Rotolo M; Edwards R; Lipson EJ; Taube JM
Ann Oncol; 2019 Apr; 30(4):589-596. PubMed ID: 30689736
[TBL] [Abstract][Full Text] [Related]
12. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors.
Damsky W; Jilaveanu L; Turner N; Perry C; Zito C; Tomayko M; Leventhal J; Herold K; Meffre E; Bosenberg M; Kluger HM
J Immunother Cancer; 2019 Jun; 7(1):153. PubMed ID: 31200747
[TBL] [Abstract][Full Text] [Related]
13. CD4
Kagamu H; Kitano S; Yamaguchi O; Yoshimura K; Horimoto K; Kitazawa M; Fukui K; Shiono A; Mouri A; Nishihara F; Miura Y; Hashimoto K; Murayama Y; Kaira K; Kobayashi K
Cancer Immunol Res; 2020 Mar; 8(3):334-344. PubMed ID: 31871122
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
15. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
16. Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
Manjarrez-Orduño N; Menard LC; Kansal S; Fischer P; Kakrecha B; Jiang C; Cunningham M; Greenawalt D; Patel V; Yang M; Golhar R; Carman JA; Lezhnin S; Dai H; Kayne PS; Suchard SJ; Bernstein SH; Nadler SG
Front Immunol; 2018; 9():1613. PubMed ID: 30123214
[TBL] [Abstract][Full Text] [Related]
17. Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody.
Yamaguchi K; Mishima K; Ohmura H; Hanamura F; Ito M; Nakano M; Tsuchihashi K; Ota SI; Wada N; Uchi H; Ariyama H; Kusaba H; Niiro H; Akashi K; Baba E
Cancer Sci; 2018 Oct; 109(10):3032-3042. PubMed ID: 30066977
[TBL] [Abstract][Full Text] [Related]
18. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.
Reschke R; Gussek P; Boldt A; Sack U; Köhl U; Lordick F; Gora T; Kreuz M; Reiche K; Simon JC; Ziemer M; Kunz M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360781
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
20. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
